Teradata Corporation (TDC) failed to extend gains with the stock declining -0.31% or $-0.09 to close the day at $29.03 on light trading volume of 1.43M shares, compared to its three month average trading volume of 1.64M. The Dayton Ohio 45342 based company has been outperforming the data storage devices group over the past 52 weeks, with the stock gaining 19.27%, compared to the industry which has advanced 57.92% over the same period. With RSI of 60.4, the stock should still continue to rise and get closer to its one year target estimate of $27.47, making it a hold for now.
Teradata Corporation provides analytic data solutions, marketing and analytic applications, and related services in the United States and internationally. Its analytic data solutions comprise software, hardware, and related business consulting and support services for data warehousing and big data analytics. The company’s products comprise Teradata Database Software that delivers near real-time intelligence; Teradata Workload-Specific Platforms; Teradata Aster Analytics Discovery Platform, which is pre-configured with Teradata Aster Database; Teradata Portfolio for Hadoop; and Teradata QueryGrid that provides access to analytics to various processing engines. It also provides Teradata Integrated Marketing Applications, which help organizations in managing marketing workflows, budget allocation, leads, analytics, and digital assets. In addition, the company provides business consulting services; technology and implementation services; cloud services; and management services for data integration, data warehouse, discovery, Hadoop, and business intelligence environments. Further, it offers customer support services, such as installation, maintenance, monitoring, back-up, and recovery services; training services; and marketing services. The company serves various industries comprising banking/financial services, communications, energy, government, insurance and healthcare, manufacturing, oil and gas, retail, travel and transportation logistics, and utilities. It has strategic partnerships with Accenture, Capgemini, Cognizant Technology Solutions, Deloitte, IBM Global Business Services, and Wipro Limited. Teradata Corporation was founded in 1979 and is headquartered in Dayton, Ohio.
Washington Prime Group Inc. (WPG) retreated with the stock falling -1.48% or $-0.14 to close at $9.31 on light trading volume of 1.43M compared its three months average trading volume of 1.94M. The Columbus Ohio 43215 based company operating under the Property Management industry has been trending up for the last 52 weeks, with the shares price now 12.64% up for the period and down by -10.57% so far this year. With price target of $10.1 and a 38.03% rebound from 52-week low, Washington Prime Group Inc. has plenty of upside potential, making it a hold with a view buy.
Washington Prime Group Inc. (NYSE:WPG.WI) operates independently of Simon Property Group Inc. as of May 28, 2014.
Heat Biologics, Inc. (HTBX) failed to extend gains with the stock declining -7.41% or $-0.08 to close the day at $1 on lower than average trading volume of 1.43M shares, compared to its three month average trading volume of 2.85M. The Durham North Carolina 27713 based company has been outperforming the biotechnology companies by -27.0106% for last three months and its recent losses have trimmed gains to 16.28% YTD, versus the biotechnology industry which is down -6.09% for the same period. The RSI of 39.13 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include viagenpumatucel-L (HS-110) that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and vesigenurtacel-L (HS-410), which is in Phase 1b clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.